Major Molecular Response Achievement in CML Patients Can Be Predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS Ratio at an Earlier Time Point of Follow-Up than Currently Recommended
暂无分享,去创建一个
P. Cony-Makhoul | J. Magaud | S. Hayette | I. Tigaud | S. Gazzo | F. Nicolini | S. Huet | M. Michallet | M. Heiblig | A. Belhabri | Denis Souche
[1] H. Einsele,et al. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib , 2014, Leukemia.
[2] R. Larson,et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. , 2014, Blood.
[3] Martin C. Müller,et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Baccarani,et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). , 2014, Blood.
[5] Nicola D. Roberts,et al. Any BCR-ABL Reduction Below 10% At 6 Months Of Therapy Significantly Improves Outcome For CML Patients With a Poor Response At 3 Months , 2013 .
[6] Martin C. Müller,et al. High BCR-ABL/GUSIS Levels At Diagnosis Are Associated With Unfavorable Responses To Imatinib , 2013 .
[7] Francisco Cervantes,et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. , 2013, Blood.
[8] H. Kantarjian,et al. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. , 2013, Blood.
[9] K. Rezvani,et al. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. , 2013, Blood.
[10] Martin C. Müller,et al. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] T. Brümmendorf,et al. Assessment of Early Molecular Response As a Predictor of Long-Term Clinical Outcomes in the Phase 3 BELA Study , 2012 .
[12] A. Vekhoff,et al. Relationship Between Molecular Responses and Disease Progression in Patients (Pts) Treated First Line with Imatinib (Im) Based Regimens: Impact of Treatment Arm within the French Spirit Trial From the French CML Group (FI LMC) , 2012 .
[13] H. Einsele,et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) , 2012, Leukemia.
[14] R. Clark,et al. Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. , 2012, Blood.
[15] Dong-Wook Kim,et al. BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management. , 2012, Blood.
[16] Katayoun Rezvani,et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Martin C. Müller,et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). , 2010, Blood.
[18] K. Rezvani,et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. , 2008, Blood.
[19] Martin C. Müller,et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. , 2008, Blood.
[20] Francisco Cervantes,et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.
[21] Simona Soverini,et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. , 2006, Blood.
[22] H. Cavé,et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program , 2003, Leukemia.
[23] F. Watzinger,et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program , 2003, Leukemia.